
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Past Returns: Outperforming stock! In past three years, the stock has provided 80.5% return compared to 10.7% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Momentum: Stock is suffering a negative price momentum. Stock is down -16.4% in last 30 days.
Smart Money: Smart money looks to be reducing their stake in the stock.
Dividend: Stock hasn't been paying any dividend.
Size: It is a small market cap company and can be volatile.
Valuation | |
|---|---|
| Market Cap | 730.2 Cr |
| Price/Earnings (Trailing) | 16.45 |
| Price/Sales (Trailing) | 1.15 |
| EV/EBITDA | 7.88 |
| Price/Free Cashflow | -33.31 |
| MarketCap/EBT | 17.34 |
| Enterprise Value | 730.2 Cr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 634.49 Cr |
| Rev. Growth (Yr) | 23.8% |
| Earnings (TTM) | 42.98 Cr |
| Earnings Growth (Yr) | 1.2% |
Profitability | |
|---|---|
| Operating Margin | 7% |
| EBT Margin | 7% |
| Return on Equity | 72.52% |
| Return on Assets | 10.38% |
| Free Cashflow Yield | -3% |
Growth & Returns | |
|---|---|
| Price Change 1W | -3% |
| Price Change 1M | -16.4% |
| Price Change 6M | -9.2% |
| Price Change 1Y | -9.2% |
| 3Y Cumulative Return | 80.5% |
| 5Y Cumulative Return | 21.7% |
| 7Y Cumulative Return | 40.6% |
| 10Y Cumulative Return | 17.5% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -51.17 Cr |
| Cash Flow from Operations (TTM) | 26.1 Cr |
| Cash Flow from Financing (TTM) | 25.73 Cr |
| Free Cash Flow (TTM) | -22.93 Cr |
| Free Cash Flow/Share (TTM) | -6.97 |
Balance Sheet | |
|---|---|
| Total Assets | 413.92 Cr |
| Total Liabilities | 354.65 Cr |
| Shareholder Equity | 59.27 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.42 |
| Debt/Equity | 2.92 |
| Interest Coverage | 0.14 |
| Interest/Cashflow Ops | 1.71 |
Dividend & Shareholder Returns | |
|---|---|
| Shares Dilution (1Y) | 6.5% |
| Shares Dilution (3Y) | 6.7% |
Past Returns: Outperforming stock! In past three years, the stock has provided 80.5% return compared to 10.7% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Momentum: Stock is suffering a negative price momentum. Stock is down -16.4% in last 30 days.
Smart Money: Smart money looks to be reducing their stake in the stock.
Dividend: Stock hasn't been paying any dividend.
Size: It is a small market cap company and can be volatile.
Investor Care | |
|---|---|
| Shares Dilution (1Y) | 6.5% |
| Earnings/Share (TTM) | 13.5 |
Financial Health | |
|---|---|
| Current Ratio | 1.11 |
| Debt/Equity | 2.92 |
Technical Indicators | |
|---|---|
| RSI (14d) | 41.9 |
| RSI (5d) | 57.86 |
| RSI (21d) | 42.96 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of Wanbury's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Wanbury ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| EXPERT CHEMICALS (INDIA) PVT LTD | 34.41% |
| KINGSBURY INVESTMENTS INC | 8.67% |
| SURESH BHATIA | 3.12% |
| AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED | 2.07% |
| SHARMIN NASSER | 1.33% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Wanbury against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|
Comprehensive comparison against sector averages
WANBURY metrics compared to Pharmaceuticals
| Category | WANBURY | Pharmaceuticals |
|---|---|---|
| PE | 16.45 | 33.70 |
| PS | 1.15 | 4.65 |
| Growth | 12.5 % | 8 % |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
WANBURY vs Pharmaceuticals (2021 - 2026)